Sanofi (SNY)
(Delayed Data from NSDQ)
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$53.10 USD
+1.90 (3.71%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $53.09 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Zacks News
Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Regeneron Pharmaceuticals, Moderna and Sanofi
5 Stocks to Buy as Coronavirus Vaccine in Human Trails Ramp Up
by Zacks Equity Research
As drug makers race to develop vaccine to fight coronavirus, we shortlist five stocks that are poised to grow on progress in clinical trials.
Coronavirus Vaccine Efforts to Aid Moderna (MRNA) Q1 Earnings?
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. While grants for development are expected to have aided revenues, increased clinical activity is expected to have increased expenses.
Why Sanofi (SNY) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Sanofi (SNY) have what it takes? Let's find out.
Regeneron's (REGN) Q1 Earnings & Sales Surpass Estimates
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings and sales on solid performance of ophthalmology drug, Eylea; asthma drug, Dupixent; and oncology drug, Libtayo.
Emergent (EBS) Earnings and Revenues Beat Estimates in Q1
by Zacks Equity Research
Emergent's (EBS) earnings and revenues surpass estimates in the first quarter of 2020. The company reaffirms its guidance for the ongoing year.
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Pfizer, Sanofi, GlaxoSmithKline and Moderna
SNY vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
SNY vs. NVO: Which Stock Is the Better Value Option?
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter 2020 results.
BioMarin (BMRN) Beats on Q1 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Is a Beat in Store for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) first-quarter results are likely to reflect strong demand for its cardiovascular drug, Vascepa.
AstraZeneca (AZN) Q1 Earnings & Sales Beat, Increase Y/Y
by Zacks Equity Research
AstraZeneca (AZN) beats estimates for both earnings and sales. It maintains its financial outlook for the year.
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Johnson & Johnson, Sanofi and Novavax
Should Value Investors Buy Sanofi (SNY) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Stocks to Benefit From Race to Develop Coronavirus Vaccines
by Zacks Equity Research
Pharmaceutical companies and scientists are relentlessly working on developing coronavirus vaccines and the progress in trails has helped stocks to rally.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming Q1 earnings call, investor focus will be on the company's progress with its seasonal influenza vaccine candidate, NanoFlu, and the COVID-19 vaccine candidate.
Big Drug Stock Q1 Earnings Due on Apr 28: MRK, PFE and NVS
by Kinjel Shah
Let us take a look at three big drug companies due to release their first-quarter financial results on Apr 28.
Company News for Apr 27, 2020
by Zacks Equity Research
Companies In The News Are: VZ, AXP, FCX, SNY.
Sanofi (SNY) Q1 Earnings, Sales Grow on Coronavirus-Led Buying
by Zacks Equity Research
Sanofi (SNY) beats estimates for both earnings and sales. Around half of the sales and earnings growth at CER was due to COVID-19 associated patient stockpiling. Stock down.
Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany
by Zacks Equity Research
Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.
Sanofi (SNY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports first-quarter results.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.